carboplatin + hydroxychloroquine + paclitaxel

This is a combination regimen consisting of three drugs—carboplatin, hydroxychloroquine, and paclitaxel—used primarily in the treatment of advanced or metastatic cancers such as non-small cell lung cancer (NSCLC). - **Carboplatin** is an organoplatinum antineoplastic alkylating agent that forms DNA crosslinks, inhibiting DNA synthesis and function, leading to apoptosis in rapidly dividing cells. - **Paclitaxel** is a taxane chemotherapeutic that stabilizes microtubules by binding to β-tubulin subunits, preventing their disassembly during mitosis and thereby halting cell division. - **Hydroxychloroquine** is an antimalarial and immunomodulatory drug that inhibits late-stage autophagy by blocking lysosomal acidification; this can sensitize tumor cells to chemotherapy by preventing them from using autophagy as a survival mechanism under stress from cytotoxic agents. The rationale for combining these agents includes targeting multiple mechanisms of tumor survival and resistance. Hydroxychloroquine’s inhibition of autophagy may enhance the cytotoxic effects of carboplatin and paclitaxel[1][2]. This combination has been studied in clinical trials for metastatic NSCLC[1], with ongoing research into its safety profile and efficacy.